Table 3.
Secondary Outcomes Among Patients Transitioning to and Newly Initiating Opioid Agonist Treatment in Primary Healthcare Clinics (N = 67).a
| Secondary outcomes | Transitioning patients N = 29 |
New patients N = 38 |
||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Baseline | After 6 months |
p-valueb | Baseline | After 6 months |
p-valueb | |
| Overall satisfaction with the program (5-point Likert scale) | 3.76 (1.15) | 4.45 (0.83) | 0.016 | – | 4.79 (0.70) | – |
| Injecting drug use during the last 30 days (number of days) | 1.31 (5.58) | 1.45 (5.80) | 0.547 | 27.87 (6.32) | 0.21 (0.62) | <0.001 |
| Opioid craving (10-point Likert scale) | 3.34 (5.59) | 3.71 (3.01) | 0.626 | 6.55 (3.33) | 3.01 (2.87) | <0.001 |
| HIV diagnosisc | 9 (29.0) | 11 (35.5) | – | 12 (30.0) | 12 (30.0) | – |
| New ART initiations (among HIV-infected) | – | 0 (0.0) | – | – | 5 (41.7) | – |
| HCV diagnosisc | 12 (38.7) | 19 (61.3) | – | 10 (25.0) | 25 (62.5) | – |
| Aggregate measure of HRQoL (0–100 scale) | 58.22 (16.59) | 53.52 (19.83) | 0.164 | 58.26 (18.59) | 65.59 (21.16) | 0.013 |
| Subjective improvement of physical health (compared to baseline) | – | 16 (55.2) | – | – | 30 (76.9) | – |
| Subjective improvement of mental health (compared to baseline) | – | 19 (65.5) | – | – | 32 (82.1) | – |
| Trust in physician (11–55 scale) | 31.07 (7.16) | 35.50 (6.66) | 0.007 | 32.39 (6.09) | 38.47 (6.55) | <0.001 |
For categorical variables data is presented in the form: N (%), and for continuous variables: mean (SD). HRQoL: health-related quality of life; ART: antiretroviral therapy.
a
This analysis is restricted to patients, for whom both baseline and 6-months follow-up data is available (except HIV and HCV diagnosis indicators).
b
p-value for continuous variables corresponds to the paired Student t-test.
c
HIV and HCV diagnosis indicators use the entire cohort (N = 31 transitioning patients, and N = 40 new patients) in the denominator.